Global Polycystic Kidney Disease (PKD) Market Report 2019: Insights, Epidemiology & Forecast 2017-2028 -

DUBLIN--()--The "Polycystic Kidney Disease (PKD) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PKDs in the 10 Emerging Markets (EM) i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Polycystic Kidney Disease (PKD) from 2017 to 2028 segmented by ten emerging markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Companies Mentioned

  • Sanofi (Genzyme)
  • Otsuka Pharmaceutical Co. Ltd.
  • Reata Pharmaceuticals Inc.

Geographies Covered

  • Asia (China, Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia, Argentina)

Study Period: 2017-2028

Polycystic Kidney Disease Epidemiology

The Polycystic Kidney Disease (PKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients) scenario of Polycystic Kidney Disease (PKD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

According to this report, the total number of prevalent cases of Polycystic Kidney Disease (PKD) in 10 EM was found to be 1,912,820 in the year 2017.

Polycystic Kidney Disease Drug Chapters

This segment of the Polycystic Kidney Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast focuses on the market revenue generated by the pharmacological treatment which are primarily symptomatic or palliative in nature. Antihypertensive drugs to slow the deterioration of Renal Function, Antibiotics to treat UTI or infected renal cysts and Analgesics to control renal pain. Immunosuppresants from another important class of drugs used only in patients undergoing Renal Transplant. It is to be noted that only a small fraction of the entire diagnosed PKD patient pool can opt for or are eligible for undergoing such surgical interventions. Therefore immunosuppressant drugs constitute a significantly lesser amount of share as compared to other supportive therapies.

Polycystic Kidney Disease Market Outlook

The Polycystic Kidney Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this report, the market of Polycystic Kidney Disease in 10EM was found to be USD 83.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Polycystic Kidney Disease, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Polycystic Kidney Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key Strengths

  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition


  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Polycystic Kidney Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Polycystic Kidney Disease market
  • To understand the future market competition in the Polycystic Kidney Disease market.

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900